Brief: Cassava Sciences Completes Patient Enrollment For Pivotal Phase 3 Trial Of Oral Simufilam In Alzheimer's Disease

Filana Therapeutics

02/10/2023 14:22

Oct 2 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES COMPLETES PATIENT ENROLLMENT FOR PIVOTAL
PHASE
3 CLINICAL TRIAL OF ORAL SIMUFILAM IN ALZHEIMER’S DISEASE
    * CASSAVA SCIENCES INC - SECOND PIVOTAL PHASE 3 CLINICAL
TRIAL IS
EXPECTED TO COMPLETE ENROLLMENT Q4 2023

Source text for Eikon:  ID:nGNX7CTXBV 
Further company coverage:  SAVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))